Clinical Trials Logo

Pneumonia clinical trials

View clinical trials related to Pneumonia.

Filter by:

NCT ID: NCT06145828 Recruiting - Septic Shock Clinical Trials

Clinical Application of Cytokine Adsorption Technique in AIDS Patients With Severe Pneumonia and/or Septic Shock

Start date: October 23, 2023
Phase:
Study type: Observational

Observing the Real-World Application Effectiveness of Cytokine Immune Adsorption Technology in AIDS Patients with Severe Pneumonia or septic shock.

NCT ID: NCT06137196 Recruiting - Pneumonia Clinical Trials

Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia

Start date: November 1, 2023
Phase:
Study type: Observational

Screening for risk factors related to lung function impairment in patients who have recovered from AIDS with severe pneumonia, to provide clinical evidence for early identification and intervention of lung function damage in this population.

NCT ID: NCT06136832 Recruiting - Vaccine Clinical Trials

Pneumonia Vaccine Education Intervention Study

PVI
Start date: May 6, 2024
Phase: N/A
Study type: Interventional

The goal of this interventional clinical trial is to investigate the impact of medicine and pharmacy-led education on patient acceptance rates of Prevnar 20 pneumonia vaccination in patients eligible to receive the vaccine. The education intervention and subsequent option to get the vaccine will be done while the patient is admitted to inpatient care, prior to discharge. The main questions the study aims to answer are: - Will supplemental education about the Prevnar 20 Pneumococcal vaccine influence patient acceptance rates when given a decision to receive it? - Is there any other statistically relevant qualitative reasoning behind the patient's final decision for accepting or refusing the vaccine?

NCT ID: NCT06134492 Recruiting - Clinical trials for Ventilator Associated Pneumonia

Acyclovir in Mechanically Ventilated Patients With Pneumonia and HSV-1 in BAL

HerpMV
Start date: February 20, 2024
Phase: Phase 3
Study type: Interventional

Almost 90 out of 100 people carry herpes simplex viruses (HSV). Once a person has been infected with the herpes viruses, he or she can't get rid of them for the rest of her/his life. For the most part, the viruses are in a dormant state. Only when the immune system is weakened, for example in the case of a serious illness or stress, are the viruses reactivated. They then mainly cause cold sores, which are harmless for healthy people and usually heal without therapy. However, especially in people with a weakened immune system, HSV can also cause serious infections, such as meningitis. In almost every second mechanically ventilated patient in intensive care who has pneumonia, HSV can be detected in the respiratory tract. This is caused by reactivation of the viruses as a result of the severe underlying disease and stress during intensive care therapy. Whether treatment of the herpes viruses (e.g. with acyclovir) is necessary in this situation and helps the patients to cure has not been clarified, especially as acyclovir can also cause side effects such as a deterioration in kidney function. Currently, the physicians decide to treat the herpes viruses in about half of the patients. Several studies have shown that patients for whom the physician decided to treat the viruses survived more often. However, all of these studies looked at the course of the disease only retrospectively and thus are subject to many biases (including physician selection of who receives treatment, missing data). A definitive conclusion as to whether herpesvirus therapy can be recommended cannot be drawn without doubt from these studies. Therefore, the investigators would like to investigate in a randomized controlled trial, i.e. patients are randomly assigned to the experimental (therapy of herpesviruses) or control group (no therapy of herpesviruses), the effect of therapy with acyclovir on survival in mechanically ventilated intensive care patients with lower respiratory tract infection (pneumonia) in whom a large amount of HSV was found in the respiratory tract. The goal of the study is to provide clarity on whether therapy will help patients recover.

NCT ID: NCT06125340 Recruiting - Clinical trials for Community-acquired Pneumonia

Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Short-course Therapy

PRESTO-2
Start date: April 17, 2024
Phase: Phase 4
Study type: Interventional

Children are commonly hospitalized because of community-acquired pneumonia (CAP). There are multiple high-quality randomized trials of short-course antibiotic therapy (3-5 days of treatment) for adults hospitalized with CAP - but there is very little evidence in children. We intend to do a pilot RCT of short-course (3-5 days) vs standard-duration (8-10 days) antibiotic therapy for children hospitalized for CAP.

NCT ID: NCT06123650 Recruiting - Pneumonia Clinical Trials

Prevalence of Pneumonia After Adding Repetitive Transcranial Magnetic Stimulation in Poststroke Dysphagia

Start date: October 22, 2023
Phase: N/A
Study type: Interventional

BACKGROUND: Dysphagia is one of the most life-threatening stroke complications. Dysphagic stroke patients are at increased risk of aspiration pneumonia. Pneumonia accounts for at least 10% of post stroke deaths within 30 days of hospitalization after stroke. rTMS is effective in improving post-stroke dysphagia and swallowing coordination after stimulation of the unaffected hemisphere, however it's efficacy on the prevalence of pneumonia has not yet been examined. Purpose of the study: To determine the effect of adding repetitive transcranial magnetic stimulation to conventional oropharyngeal physical therapy program on the prevalence of aspiration pneumonia in in patients with post stroke dysphagia.

NCT ID: NCT06114888 Recruiting - Clinical trials for Community-acquired Pneumonia

Optimizing Care for Children Hospitalized With Community-acquired Pneumonia: Novel Diagnostics

PRESTO-1
Start date: April 17, 2024
Phase: N/A
Study type: Interventional

Children are commonly hospitalized because of community-acquired pneumonia. Despite the fact that many of these children have viral disease, a majority is treated with antibiotics. These antibiotics will not accelerate recovery in those with viral pneumonia and can cause harm. We are interested in exploring whether the MeMed BV - a composite biomarker assay - could be used to improve antibiotic prescribing in these children by identifying those who likely have viral disease. This proposal describes a feasibility randomized trial of this diagnostic intervention.

NCT ID: NCT06114784 Recruiting - Severe Pneumonia Clinical Trials

Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study

MASS
Start date: September 25, 2023
Phase:
Study type: Observational

This study was a prospective multicenter cohort of severe pneumonia. And by collecting clinical samples to clarify the correlation between lung microbiome, intestinal microbiome, host susceptibility, and prognosis of severe pneumonia patients.

NCT ID: NCT06112938 Recruiting - Clinical trials for Stenotrophomonas Maltophilia Infection

Alternative Treatment Strategies for Stenotrophomonas Maltophilia Pneumonia

Start date: July 21, 2022
Phase:
Study type: Observational

Multi center, retrospective chart review of patients admitted to MHS hospitals from April 1, 2017 to March 31, 2022. Patients will be identified through the electronic medical record, and data from those that meet the study inclusion and exclusion criteria will be analyzed. Minimum inhibitory concentration (MIC) data will be interpreted per Clinical & Laboratory Standards Institute (CLSI) standards to determine local patterns of resistance. Multivariable logistic regression will be performed to determine predictors of mortality for S. maltophilia isolates.

NCT ID: NCT06106126 Recruiting - COVID-19 Pneumonia Clinical Trials

Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function

Start date: February 10, 2023
Phase: N/A
Study type: Interventional

This si a single-center, non-randomized, open, parallel, single-dose trial was designed to evaluate the safety and pharmacokinetic characteristics of GST-HG171 tablets in subjects with impaired renal function.